Valuation
- Market cap
- 2,268,000
- Revenue TTM
- $20,000
- Net income TTM
- $-6,610,000
- PE ratio
- —
- Forward PE
- —
- Profit margin
- —
- Debt to equity
- —
Trading
- Volume
- 11,938
- Avg volume
- 455,542
- Day's range
- $3.22 – $3.37
- Shares out
- 656,000
- Stochastic %K
- 24%
- Beta
- 3.16
- Analysts
- Strong Sell
- Price target
- $13.50
Company profile
HeartSciences Inc., a medical technology company, focuses on advancing electrocardiography (ECG) through the integration of artificial intelligence. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfuncti...
Show more
HeartSciences Inc., a medical technology company, focuses on advancing electrocardiography (ECG) through the integration of artificial intelligence. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test; and MyoVista Insights, a cloud-native vendor- and device-agnostic ECG management platform. The company was formerly known as Heart Test Laboratories, Inc. and changed its name to HeartSciences Inc. in October 2024. HeartSciences Inc. was incorporated in 2007 and is headquartered in Southlake, Texas.
- Industry
- Medical Devices
- Sector
- Healthcare
- Phone
- 682 237 7781
- Website
- https://heartsciences.com
- Address
- 550 Reserve Street, Suite 360, Southlake, United States
Latest news
No headlines yet.
